ALT - Altimmune, Inc.

2.6
-0.030   -1.154%

Share volume: 5,638,491
Last Updated: 04-30-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.11%

PREVIOUS CLOSE
CHG
CHG%
$2.63
-0.03
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 21%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.86%
1 Month
-4.86%
3 Months
-46.27%
6 Months
-31.50%
1 Year
-46.27%
2 Year
-57.15%
Key data
Stock price
$2.60
P/E Ratio 
N/A
DAY RANGE
$2.58 - $2.68
EPS 
-$1.00
52 WEEK RANGE
$2.72 - $7.73
52 WEEK CHANGE
-$47.81
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
130.070 M
DIVIDEND
$2.91
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
2.77
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$9,188,016
AVERAGE 30 VOLUME 
$4,630,302
Company detail
CEO: Vipin K. Garg
Region: US
Website: altimmune.com
Employees: 50
IPO year: 2005
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Altimmune, Inc. focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.

Recent news